TXG 10x Genomics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: integrated life sciences technology products and software for analyzing biological systems with high resolution and scale
• • New acquisition in 2025: Scale Biosciences, adding QuantumScale single cell RNA and methylation kits to single cell portfolio
• • Strategic emphasis on expanding spatial portfolio with Visium CytAssist instrument and new Xenium analyzer for in situ RNA analysis
• • Employee count increased to 1,178 in 2025, including 332 in R&D and 473 in sales/marketing/support
• • Noteworthy: Sold 1,007 instruments and 424,000 consumable reactions in 2025, reflecting growth in consumable reactions despite slight instrument sales decline vs 2024

Risk Factors

• • Regulatory/legal risk: Patent litigation settlements with Vizgen (Feb 2025, $26M upfront) and Bruker (May 2025, $68M installments) impacting license and royalty revenue
• • Geopolitical/macroeconomic risk: Foreign currency fluctuations affecting revenue, mainly in euro, GBP, and JPY markets, causing realized/unrealized gains/losses of $4.6M in 2025
• • Operational/supply chain risk: $7.8M increase in inventory write-downs due to product mix changes and manufacturing cost pressures in 2025
• • Competitive/market disruption risk: Price declines of Spatial instruments caused 39% revenue drop ($35.9M) in 2025 amid competition and market pricing pressure
• • Financial/structural risk: Dependence on contingent consideration of up to $30M from Scale Bio acquisition, with fair value remeasured quarterly causing revenue and income fluctuation

Management Discussion & Analysis

• • Revenue and profitability details not disclosed in provided text
• • No segment performance data included
• • Cash flow, buybacks, dividends, and capex data not included
• • Forward-looking statements caution on risks and uncertainties without specific guidance

What are the latest TXG SEC filings in 2026?

10x Genomics, Inc. (TXG) has filed a 10-K annual report on February 13, 2026, a 10-Q quarterly report on May 8, 2026, an 8-K current report on June 8, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TXG file its most recent 10-K annual report?

10x Genomics, Inc. (TXG) filed its most recent 10-K annual report on February 13, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TXG 10-Q quarterly reports?

10x Genomics, Inc. (TXG)'s most recent 10-Q quarterly report was filed on May 8, 2026. SignalX displays every TXG 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TXG filed recently?

10x Genomics, Inc. (TXG)'s most recent 8-K was filed on June 8, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TXG insider trading activity (Form 4)?

SignalX aggregates every TXG Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TXG file with the SEC?

10x Genomics, Inc. (TXG) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TXG filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for 10x Genomics, Inc. (TXG).

What is TXG's SEC CIK number?

10x Genomics, Inc. (TXG)'s SEC CIK (Central Index Key) number is 1770787. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1770787 to look up all TXG filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TXG return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from 10x Genomics, Inc. (TXG) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.